Early benefit assessment for new drugs 2021: G-BA sets a record with 146 completed procedures

Federal Joint Committee (G-BA)

10 January 2022 - At the beginning of the year, the Federal Joint Committee (G-BA) took stock of its assessment of new drugs in 2021. 

In addition to a record number of assessments, the G-BA was able to award the highest seal of quality "significant additional benefit" five times. 

The year 2021 was also diverse in terms of content and therapy: in addition to many new cancer drugs, the G-BA also evaluated the first antiviral drug against COVID-19, novel gene therapy drugs and high-priced active ingredients against spinal muscular atrophy.

Read G-BA press release [German]

Michael Wonder

Posted by:

Michael Wonder